Pathway for Softgel vs Tablet Comparison [Design Issues]

posted by Obinoscopy  – USA, 2018-05-15 19:04 (897 d 20:10 ago) – Posting: # 18764
Views: 1,982

Dear bebac_fan,

» I think this would need to go through a NDA/505(b)(2) pathway rather than an ANDA.

I share the same view with you on this.

However I have a case where a BE study was conducted comparing Metronidazole tablet (Reference) with Metronidazole soft gel (test). Both were IR. Is this acceptable?



Complete thread:

 Admin contact
21,179 posts in 4,414 threads, 1,477 registered users;
online 5 (0 registered, 5 guests [including 3 identified bots]).
Forum time: Thursday 14:15 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz